Lantheus (LNTH) to Release Earnings on Wednesday

Lantheus (NASDAQ:LNTH - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $1.40 per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 EPS. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Lantheus Price Performance

NASDAQ LNTH traded down $0.05 during trading hours on Wednesday, reaching $110.04. The company's stock had a trading volume of 54,834 shares, compared to its average volume of 954,637. The company's 50-day moving average is $107.80 and its two-hundred day moving average is $93.85. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a market capitalization of $7.63 billion, a price-to-earnings ratio of 16.83 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the company's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now directly owns 454,923 shares of the company's stock, valued at $43,445,146.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,981 shares of company stock valued at $2,689,156 over the last 90 days. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JMP Securities decreased their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Finally, Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.